NS3 amino acid profile at time of failurea | N | Return to baseline at EOSa,c,d, n (%) | Change to new profile at EOSa,c, n (%) | Follow-up timeb, median, weeks | Follow-up timeb, range, weeks |
---|---|---|---|---|---|
All HCV geno/subtypes | |||||
Enrolled patients with no SVR at LPVPS | 49 | ||||
Number of patients (at failure with EOS) with sequencing informationc | 48 | 37 (77.1) | 3 (6.3) | 177.7 | (46.7–230.3) |
No emerging NS3 amino acid substitution | 5 | 0 (0.0) | 0 (0.0) | 174.0 | (111.3–192.0) |
Any emerging NS3 amino acid substitution | 43 | 37 (86.0) | 3 (7.0) | 179.9 | (46.7–230.3) |
HCV GT1a with Q80K at baseline | |||||
Enrolled patients with no SVR at LPVPS | 10 | ||||
Number of patients (at failure with EOS) with sequencing informationc | 10 | 8 (80.0) | 0 (0.0) | 146.9 | (96.1–230.3) |
No emerging NS3 amino acid substitution | 1 | 0 (0.0) | 0 (0.0) | 111.3 | – |
Any emerging NS3 amino acid substitution | 9 | 8 (88.9) | 0 (0.0) | 180.9 | (96.1–230.3) |
R155K | 8 | 8 (100.0) | 0 (0.0) | 146.9 | (96.1–230.3) |
D168E | 1 | 0 (0.0) | 0 (0.0) | 192.4 | – |
HCV GT1a without Q80K at baseline | |||||
Enrolled patients with no SVR at LPVPS | 14 | ||||
Number of patients (at failure with EOS) with sequencing informationc | 14 | 12 (85.7) | 1 (7.1) | 182.6 | (98.9–222.0) |
Any emerging NS3 amino acid substitution | 14 | 12 (85.7) | 1 (7.1) | 182.6 | (98.9–222.0) |
R155K | 4 | 3 (75.0) | 0 (0.0) | 179.4 | (98.9–198.0) |
D168V | 2 | 2 (100.0) | 0 (0.0) | 141.6 | (138.0–145.1) |
Q80R + D168E | 2 | 2 (100.0) | 0 (0.0) | 214.4 | (210.0–218.7) |
R155K + D168E | 2 | 1 (50.0) | 1 (50.0) | 182.6 | (182.1–183.0) |
D168A | 1 | 1 (100.0) | 0 (0.0) | 134.6 | – |
D168E | 1 | 1 (100.0) | 0 (0.0) | 192.0 | – |
R155K + D168A | 1 | 1 (100.0) | 0 (0.0) | 189.0 | – |
R155K + D168V | 1 | 1 (100.0) | 0 (0.0) | 222.0 | – |
HCV GT1b | |||||
Enrolled patients with no SVR at LPVPS | 24 | ||||
Number of patients (at failure with EOS) with sequencing informationc | 24 | 17 (70.8) | 2 (8.3) | 174.9 | (46.7–225.1) |
No emerging NS3 amino acid substitution | 4 | 0 (0.0) | 0 (0.0) | 175.3 | (157.1–192.0) |
Any emerging NS3 amino acid substitution | 20 | 17 (85.0) | 2 (10.0) | 174.9 | (46.7–225.1) |
D168V | 10 | 10 (100.0) | 0 (0.0) | 148.5 | (46.7–225.1) |
Q80R + D168E | 2 | 0 (0.0) | 1 (50.0) | 169.5 | (126.9–212.1) |
D168A | 1 | 1 (100.0) | 0 (0.0) | 188.4 | – |
D168E | 1 | 1 (100.0) | 0 (0.0) | 169.3 | – |
D168E/V | 1 | 1 (100.0) | 0 (0.0) | 220.3 | – |
Q80K + D168E | 1 | 1 (100.0) | 0 (0.0) | 174.6 | – |
Q80K + S122R + D168E | 1 | 0 (0.0) | 1 (100.0) | 175.9 | – |
Q80R + D168E/V | 1 | 1 (100.0) | 0 (0.0) | 196.3 | – |
Q80R + S174F/Y | 1 | 1 (100.0) | 0 (0.0) | 166.4 | – |
V132I + D168V | 1 | 1 (100.0) | 0 (0.0) | 221.0 | – |